环孢菌素A联合造血细胞因子治疗骨髓增生异常综合征的临床疗效

The Clinical Effect of Cyclosporin A Combined With Hematopoietic Growth5 Factor in Treatment of Patients With Myelodysplastic Syndrome

目的探讨环孢菌素A(CsA)联合造血细胞因子治疗骨髓增生异常综合征(MDS)的临床疗效。方法采用环孢菌素A(CsA)联合造血细胞因子治疗难治性贫血(MDS-RA)患者19例,定期观察患者外周血象和骨髓细胞形态学、并随诊观察远期疗效。结果19例患者治疗后总有效率为73.7%(14/19),全部病例未见严重副作用,未发现向白血病转化的病例,治疗后骨髓细胞形态学未见改变。结论环孢菌素A(CsA)联合造血细胞因子治疗MDS-RA疗效可靠。

Objective To explore chnical result of cyclosporinA （CsA） and hematopoietic growth factor for treatment of myelodysplastic syndrome （ MDS ） with refractory anemia （ RA ）. Methods 19 cases of MDS - RA were treated with CsA and hematopoietic growth factor, while the changes of blood cells count, bone marrow and long- term therapy effect were observed. Result The total effective rate of 19 patients was 73.7% （8/19}, no serious side effects occurred in all treated patients, the patients＇ anemia was improved and all transfusion - dependent patients achieved transfusion independence, the hematological of the bone marrow had no changes. Conclusion The treatment of MDS - RA by CsA combined with hematopoietic growth factor is effective.